Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-033 in Adult Participants

NCT07662096 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.

NCT NCT07662096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-033 in Adult Participants
Lead sponsor
Arrowhead Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
June 25, 2026
Completion date
July 1, 2028
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration